ReviewCells2026
Plasma Proteomics in IgA Nephropathy: From Circulating Biomarkers to Molecular Endotypes.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is a primary glomerular disease with various clinical features, disease progression, and therapeutic responses that affects people worldwide. Currently, risk stratification depends primarily on clinical variables, together with the Oxford MEST-C classification, which indicates structural damage. However, these approaches only provide a limited explanation of the molecular mechanisms responsible for the disease. Recent proteomic discoveries have enabled researchers to characterize proteins not only in blood plasma and urine but also in kidney tissues, opening new avenues for understanding the underlying biology of IgAN. Our review addresses existing findings in plasma proteomic studies and, at the same time, brings into the picture developments in urinary and tissue proteomic profiling, thereby demonstrating that molecular profiling has been essential for further understanding of IgAN pathogenesis. Several research studies highlight complement system dysregulation, immune system overactivity, extracellular matrix remodeling, and metabolic disturbances as the leading factors linked to disease activity and progression. Even after many years in biomarker discovery, the development and clinical application of single plasma-based molecules as markers for disease detection remain challenging. Proteomic signatures based on the various processes involved in a single disease consistently outperform single protein identification in describing complexity and distinguishing molecular endotypes. We also present the current status of proteomic-based profiling methods, cross-linking proteomics with other data sources, and the remaining clinical application barriers. Through the development of this technology, proteomics has not only enabled the discovery of new biomarkers but also provided a framework for viewing IgAN as a heterogeneous disease comprising distinct molecular endotypes. Overall, current evidence indicates that proteomics is evolving from biomarker discovery toward molecular disease classification, with the potential to improve prognostication, guide mechanism-based therapeutic selection, and advance precision nephrology in IgAN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.